Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Notes Payables (2016 - 2025)

China Pharma Holdings' Notes Payables history spans 12 years, with the latest figure at $1.4 million for Q4 2025.

  • For Q4 2025, Notes Payables rose 25.34% year-over-year to $1.4 million; the TTM value through Dec 2025 reached $1.4 million, up 25.34%, while the annual FY2025 figure was $1.4 million, 25.34% up from the prior year.
  • Notes Payables reached $1.4 million in Q4 2025 per CPHI's latest filing, up from $1.4 million in the prior quarter.
  • In the past five years, Notes Payables ranged from a high of $4.6 million in Q3 2022 to a low of $315428.0 in Q3 2024.
  • Average Notes Payables over 5 years is $1.7 million, with a median of $1.4 million recorded in 2025.
  • Peak YoY movement for Notes Payables: tumbled 84.44% in 2024, then soared 348.07% in 2025.
  • A 5-year view of Notes Payables shows it stood at $1.2 million in 2021, then surged by 222.25% to $3.8 million in 2022, then plummeted by 70.16% to $1.1 million in 2023, then rose by 0.99% to $1.1 million in 2024, then grew by 25.34% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Notes Payables are $1.4 million (Q4 2025), $1.4 million (Q3 2025), and $1.4 million (Q2 2025).